15 výsledky
The present invention relates to methods and compositions that provide for the diagnosis and treatment of prostatic intraepithelial neoplasia. A particular aspect of the invention relates to methods and compositions containing compounds which inhibit phospholipase A.sub.2, particularly those that
TECHNICAL AREA OF THE INVENTION
The invention relates to the area of cancer chemopreventative agents. More particularly, the invention relates to the area of screening assays for cancer chemopreventative agents.
BACKGROUND OF THE INVENTION
Because common epithelial cancers have resisted most
The present invention relates to methods and compositions that prevent or inhibit metastases of cancers of epithelial cell origin, especially human prostate cancers. A particular aspect of the invention relates to methods and compositions that inhibit arachidonic acid release in cells of these
The present invention relates to methods and compositions that provide for the diagnosis and treatment of prostatic intraepithelial neoplasia. A particular aspect of the invention relates to methods and compositions containing compounds which inhibit phospholipase A.sub.2, particularly those that
The present invention relates to methods and compositions that provide for the diagnosis and treatment of prostatic intraepithelial neoplasia. A particular aspect of the invention relates to methods and compositions containing compounds which inhibit phospholipase A.sub.2, particularly those that
FIELD OF THE INVENTION
The present invention is in the field of the prevention and treatment of cancer. More specifically, this invention relates to the use of 5-lipoxygenase inhibitors and PPAR ligands or derivatives thereof in preventing and treating cancer.
BACKGROUND OF THE INVENTION
The
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of radiation biology and cell biology. More particularly, it concerns the attenuation of the effect of ionizing radiation induced activation of cytokines, such as tumor necrosis factor, by
The present invention relates to methods for gauging the metastatic potential of tumors of epithelial cell origin by determining an effector of arachidonic acid release in cells of a tumor-containing tissue. This aspect of the invention particularly relates to determining uteroglobin protein or mRNA
TABLE OF CONTENTS
1. Background of the Invention 1.1 Field of the Invention 1.2 Description of the Relevant Art 2. Summary of the Invention 3. Brief Description of the Drawings 4. Detailed Description of the Invention 4.1 Definitions 4.2.1 Cyclooxygenases and Prostaglandins 4.2.2 COX-2 Selective
GOVERNMENT SUPPORT CLAUSE
This invention is made with federal grant money from the National Foundation for Cancer Research. The United States Government has certain rights in this invention.
TABLE OF CONTENTS
1. Background of the Invention 1.1 Field of the Invention 1.2 Description of the Relevant
FIELD OF THE INVENTION
The present invention relates to inhibitors of PGHS-2 transactivation function and in particular to methods of screening for inhibitors of PGHS-2 transactivation.
BACKGROUND OF THE INVENTION
Prostaglandin-endoperoxide H synthase (PGHS) is a rate-limiting enzyme in the
FIELD OF THE INVENTION
The invention relates to the enhancement of the bodily action of interferons.
GENERAL BACKGROUND
The outline of production of 1-series and 2-series PGs in the body is believed to be as shown in the following diagram: ##STR1##
The broad outline of this pathway is well known,
FIELD OF THE INVENTION
The present invention generally relates to the use of anti-angiogenic agents in the cure of cell proliferative disorders including cancer and other disorders caused by uncontrolled angiogenic activity in the body. More particularly, the invention is directed to the efficacious
FIELD OF THE INVENTION
The present invention generally relates to the use of anti-angiogenic agents in the cure of cell proliferative disorders including cancer and other disorders caused by uncontrolled angiogenic activity in the body. More particularly, the invention is directed to the efficacious
FIELD OF THE INVENTION
The present invention generally relates to the use of anti-angiogenic agents in the cure of cell proliferative disorders including cancer and other disorders caused by uncontrolled angiogenic activity in the body. More particularly, the invention is directed to the efficacious